Jiangsu Hengrui Medicine Registers New Chemo Drug in China; Shares Rally 10% - Marketscreener.com

1 year ago 49

Homepage Equities China Shanghai Stock Exchange Jiangsu Hengrui Medicine Co., Ltd. News Summary     600276   CNE0000014W7 (600276) Add to my list   Report End-of-day punctuation Shanghai Stock Exchange  -  2023-01-12 39.27 CNY   +3.92% 01:08a Jiangsu Hengrui Medicine Registers New Chemo Drug successful China; Shares Rally 10% MT 01/05 Tranche Update connected Jiangsu Hengrui Medicine Co., Ltd.'s Equity Buyback Plan announced connected March 14, 2022. CI 2022 Jiangsu Hengrui Pharma Gets Regulatory Nod For Anesthesia MT Summary Quotes Charts News Ratings Calendar Company Financials Consensus Revisions Funds   Summary Most relevant All News Analyst Reco. Other languages Press Releases Official Publications Sector news 01/16/2023 | 01:08am EST MT Newswires 2023 Stocks mentioned successful the article Change Last 1st jan. JIANGSU HENGRUI MEDICINE CO., LTD.  3.92% 39.27 1.92% UNITED STATES DOLLAR (B) / CHINESE YUAN IN HONG KONG (USD/CNH)  0.05% 6.70976 -3.12% All quality about JIANGSU HENGRUI MEDICINE CO., LTD. 01:08a Jiangsu Hengrui Medicine Registers New Chemo Drug successful China; Shares Rally 10% MT 01/05 Tranche Update connected Jiangsu Hengrui Medicine Co., Ltd.'s Equity Buyback Plan announced on.. CI 2022 Jiangsu Hengrui Pharma Gets Regulatory Nod For Anesthesia MT 2022 Hengrui Medicine Plans to Sell Shares to Fund Purchase of 51% Stake successful Local Coal Miner MT 2022 Fire Rock CFO Resigns MT 2022 US FDA Approves Jiangsu Hengrui's MRI Contrast Agent MT 2022 Hengrui Pharmaceuticals' Anti-Cancer Drug Combination Put successful Regulator's Priority Revie.. MT 2022 Hengrui Pharmaceuticals Unit Gets Clinical Trial Approval for Malignant Tumor Treatment.. MT 2022 COP27: Major nutrient firms item plans to destruct deforestation by 2025 RE 2022 Jiangsu Hengrui Medicine's Q3 Profit Slumps 32% arsenic Revenue Slides 17% MT More news Analyst Recommendations on JIANGSU HENGRUI MEDICINE CO., LTD. 2022 Nomura Adjusts Jiangsu Hengrui Pharmaceuticals' Price Target to 34.13 Yuan From 31.71 Y.. MT 2022 Nomura Adjusts Jiangsu Hengrui Pharmaceuticals' Price Target to 31.71 Yuan From 55.66 Y.. MT More recommendations Financials Sales 2022 22 353 M 3 331 M 3 331 M Net income 2022 4 267 M 636 M 636 M Net currency 2022 18 744 M 2 793 M 2 793 M P/E ratio 2022 58,6x Yield 2022 0,33% Capitalization 250 B 37 327 M 37 327 M EV / Sales 2022 10,4x EV / Sales 2023 9,04x Nbr of Employees 24 491 Free-Float 48,4% More Financials Chart JIANGSU HENGRUI MEDICINE CO., LTD. Duration : Period : Full-screen chart Technical investigation trends JIANGSU HENGRUI MEDICINE CO., LTD. Short Term Mid-Term Long Term Trends Neutral Neutral Bullish Technical analysis Income Statement Evolution More Financials Consensus Sell Buy Mean consensus BUY Number of Analysts 20 Last Close Price 39,27 CNY Average people price 50,91 CNY Spread / Average Target 29,6% Consensus EPS Revisions More Estimates Revisions Managers and Directors Wei Dong Chairman-Supervisory Board Piao Yang Sun Chairman Yu Xu Compliance Manager Shuang Xue Independent Director Qian Wang Independent Director More astir the company Sector and Competitors 1st jan. Capi. (M$) JIANGSU HENGRUI MEDICINE CO., LTD. 1.92% 37 327 JOHNSON & JOHNSON -1.82% 453 430 ELI LILLY AND COMPANY -1.15% 343 603 NOVO NORDISK A/S -0.15% 307 649 MERCK & CO., INC. 1.17% 284 598 ABBVIE INC. -4.96% 271 546 More Results

1. Homepage
2. Health
3. Jiangsu Hengrui Medicine Registers New Chemo Drug in China; Shares Rally 10% - Marketscreener.com